Safety, efficacy, and immunogenicity of a replication-defective human cytomegalovirus vaccine, V160, in cytomegalovirus-seronegative women: a double-blind, randomised, placebo-controlled, phase 2b trial.
Lancet Infect Dis
; 23(12): 1383-1394, 2023 Dec.
Article
in En
| MEDLINE
| ID: mdl-37660711
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Vaccines
/
Cytomegalovirus Infections
/
Cytomegalovirus Vaccines
Type of study:
Clinical_trials
/
Guideline
/
Prognostic_studies
Limits:
Adolescent
/
Adult
/
Child
/
Female
/
Humans
Language:
En
Journal:
Lancet Infect Dis
Journal subject:
DOENCAS TRANSMISSIVEIS
Year:
2023
Document type:
Article
Affiliation country:
Country of publication: